Two studies investigating tumor tissue or circulating DNA (ctDNA) of patients enrolled in the AURA3 trial associated this mutation in either blood or tissue samples with shorter progression-free survival (PFS) in patients who received first-line EGFR-TKI treatment [17,18]. Here, EGFR is linked to neoplasm.